

For Management of Endometriosis

Egolix 150/200
Elagolix 150/200 mg

Innovative Solution for Endo[®] Pain Relief

A monotherapy designed to achieve an optimal balance between efficacy and safety in endometriosis^{1,2,3}

Fast onset of action²

- LH & FSH suppression within 4-6 hr
- Estradiol suppression within ~24 hours

Flexible dosing as per individual patient's need¹

Systematic review and meta-analysis published in ACOG Aug 23

Elagolix demonstrated better reduction in Dysmenorrhea, NMPP & dyspareunia compared to Oral GnRH antagonists with add-back⁴

Personalizing Endometriosis Care: 20+ Years Experience with Modern GnRH antagonist - Elagolix


Sanjay K. Agarwal, MD, FACOG
Director, Center for Endometriosis Research and Treatment
Department of Ob/Gyn and Reproductive Sciences,
University of California, San Diego
www.cert.ucsd.edu

**Endometriosis Conclave:
Insights on Elagolix**


For Management of Endometriosis

Egolix 150/200
Elagolix 150/200 mg

Innovative Solution for Endo[®] Pain Relief



Senora





For Management of Endometriosis

Egolix 150/200
Egolix 150/200 mg

Innovative Solution for Endo* Pain Relief

FOGSI Updates in Endometriosis : Dec 2025

*Egolix can be considered as an emerging, potential first-line therapeutic approach in the management of endometriosis**

Scan the QR code to download the FOGSI Endometriosis Update (December 2025)

Innovative Solution for Endo Pain Relief
200 mg
Updates in Endometriosis: Dec 2025

and chapters in OBGYN

a Bharathi

Blue Crimson, Janitri,

FOGSI Updates in Endometriosis: Dec 2025

Elagolix can be considered as an emerging, potential first-line therapeutic approach in the management of endometriosis

Scan the QR code to download the FOGSI Endometriosis Update (December 2025)



Egoli
Innovative Solution for Endometriosis

USFDA
CDSCO

Check for updates on the Indian Pharmacopoeia (IP) website

For more information, visit www.egoli.com

Senora





For Management of Endometriosis
Egolix 150/200
Egolix 150/200 mg
Innovative Solution for Endo Pain Relief

FOGSI Updates in Endometriosis : Dec 2023

Egolix can be considered as an emerging, potential first-line therapeutic approach in the management of endometriosis.

For download the video (private link)





For Management of Endometriosis

Egolix 150/200

Egolix 150/200 mg

Innovative Solution for Endo* Pain Relief

FOGSI Updates in Endometriosis | Dec 2023

Egolix can be considered as an emerging, potential first-line therapeutic approach in the management of endometriosis

Scan the QR code to download the FOGSI Endometriosis Signature (December 2023)





© 2024. All rights reserved. For more information, visit [www.six.com](#)



For Management of Endometriosis
Egolix 150/200
Innovative Solution for Endo Pain Relief

A monotherapy designed to achieve an optimal balance between efficacy and safety in endometriosis^{1,2}

Fast onset of action³

• LUT & PMS improvement within 2-6 hr
• Endometrial suppression within ~24 hours

Provides relief as per individual patient's need⁴

Symptoms: review and meta-analysis published in 2020, Aug 25

Egolix demonstrated better reduction in Dysmenorrhea, NMPP & dyspareunia compared to Oral GnRH antagonists with add-back⁵



www.bsog.in

BANGALORE SOCIETY OF OBSTETRICS & GYNAECOLOGY (Regd.)

Case Study – Elagolix Reduction in Endometrioma Size

- 34-year-old G3P2A1 female patient
- Long-standing history of dysmenorrhea, deep pelvic pain, and dyspareunia controlled by oral contraceptives.
- She underwent laparoscopic bilateral tubal sterilization and multiple endometriotic implants were observed in the left uterosacral ligament, posterior cul-de-sac, and deep peritoneal pocket.
- Postoperatively the patient was started on **Elagolix 150 mg daily**
- **Following initiation of therapy with Elagolix, the patient reported a significant improvement in her symptoms and quality of life.**
- On second look laparoscopy, **a marked reduction in size and number of implants were observed**

A marked reduction of disease was observed both symptomatically and on direct visualization of lesions with Elagolix 150 mg.

Abstracts / Journal of Minimally Invasive Gynecology 26 (2019) S98-S231

For Management of Endometriosis
Egolix 150/200
Innovative Solution for Endo Pain Relief

FOGSI Update on Endo 2020

Egolix can be considered as an emerging, potential first-line therapeutic approach in the management of endometriosis⁶

Based on 24 weeks of treatment the Health Economics, Quality of Life and Patient Satisfaction Study (HEQOLIS)



Endometriosis Conclave: Insights on Elagolix

For Management of Endometriosis
Egolix 150/200
Innovative Solution for Endo Pain Relief




R et. al.)²

ate to severe disease
ometriosis associated

Elagolix 150/200
Elagolix 150/200 mg
Innovative Solution for Endo[®] Pain Relief


FOGSI Updates in Endometriosis : Dec 2025
Elagolix can be considered as an emerging, potential first-line therapeutic approach in the management of endometriosis

Scan the QR code to download the FOGSI Endometriosis Update (December 2025)



Precision is the
New Standard.

Scan to
MA
Digital



BSOG

DR. JAGANNATH DIXIT

- Head and Lead Consultant - Department of Surgical Oncology and Programme Director – Robotics
- His areas of expertise also include HIPEC (Hyperthermic Intraperitoneal Chemotherapy) procedures
- Fellowship & Membership
 - Clinical Robotic Society Association (CRSA)
 - Indian Association of Surgical Oncology (IASO)
 - Association of Minimal Access Surgeons of India (AMASI)
 - Indian Association of Gastrointestinal and Endoscopic Surgery (IAGES)
 - International College of Surgeons (ICS)
 - The Indian Society for Disease of Esophagus and Stomach (ISDE)



25+ years of experience in Surgical Oncology with focus on Gastrointestinal malignancies.
Proficient in Minimally Invasive and Robotic Oncologic Surgeries.
Trained in Robotic Surgery at premier centers in South Korea, China, and Japan (2015–2020).
Specialized in Cytoreductive Surgery and HIPEC (National Cancer Institute, Milan – 2016).



A multidisciplinary
dialogue on risk-adapted,
molecular-driven
endometrial cancer care.

For Management of Endometriosis
Egolix 150/200
Eloglix 150/200 mg
Innovative Solution for Endo[®] Pain Relief

A monotherapy designed to achieve an optimal balance between efficacy and safety in endometriosis^{1,2,3}

Fast onset of action²

- LH & FSH suppression within 4-6 hr
- Estradiol suppression within ~24 hours

Flexible dosing as per individual patient's need⁴

Systematic review and meta-analysis published in ACOG Aug/25
Egolix demonstrated a reduction in Dysmenorrhea, NM, and anemia compared to Oral GnRH analogues with add-back⁴

FOCUS
Egolix
poten
the n

**Endometriosis
Conclave:
Insights on Elagolix**


For Management of Endometriosis
Egolix 150/200
Eloglix 150/200 mg
Innovative Solution for Endo[®] Pain Relief

Endometriosis Management in India: Expert Panel Perspectives



Endometriosis Conclave: Highlights on Elagolix


Senöra
a SUN PHARMA division



For Management of Endometriosis
Egolix 150
200
Innovative Solution for Endo Pain Relief

FOGSI Updates in
Endometriosis:
Dec 2025

Elagolix can be considered as
an emerging, potential first-line
therapeutic approach in the
management of endometriosis

Scan the QR code to download the
FOGSI Endometriosis Update
(December 2025)



Endometriosis Conclave: Insights on Elagolix



triosis
ix 150/200
00 mg
r Endo Pain Relief

Designed to
improve tolerance between
endometriosis 1,2,3

Flexible dosing
as per individual
patient's need 2

Published in ACOG Aug'25

Greater reduction in
dysmenorrhea compared
to placebo add-back 4

5
aging,
which in

For Management of Endometriosis
Egolix 150/200
Innovative Solution for Endo Pain Relief

FOGSI Updates in
Endometriosis:
Dec 2025

**Egolix can be considered as
an emerging, potential first-line
therapeutic approach in the
management of endometriosis 6,8

Scan the QR code to download the
FOGSI Endometriosis Update
(December 2025)

